title: Medical castration using megestrol acetate and minidose estrogen.
abstract: Sixty-two men who presented with previously untreated metastatic carcinoma of the prostate (D0: 10 patients; D1: 29 patients; D2: 23 patients) received oral megestrol acetate (80 mg twice daily) and minidose estrogen (diethylstibestrol 0.1 mg or ethinyl estradiol 0.05 mg once daily) as a means of achieving total androgen ablation (testicular and adrenal). A high incidence of feminizing side effects (70-74%), a higher than expected rate of cardiovascular complications (18%), an unexpected need for cortisone replacement (13%), and failure of patients with Stage D2 disease to obtain results better than those of standard therapy during the first year of observation suggest this regimen offers no advantage over other more conventional therapy.
authors.affiliation: Department of Urology, University of Texas, M. D. Anderson Hospital and Tumor Institute, Houston.
authors.forename: D E
authors.initials: DE
authors.lastname: Johnson
authors.forename: R J
authors.initials: RJ
authors.lastname: Babaian
authors.forename: D A
authors.initials: DA
authors.lastname: Swanson
authors.forename: A C
authors.initials: AC
authors.lastname: von Eschenbach
authors.forename: K I
authors.initials: KI
authors.lastname: Wishnow
authors.forename: D
authors.initials: D
authors.lastname: Tenney
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy*; D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D002318:Cardiovascular Diseases / Q000139:chemically induced; D002986:Clinical Trials as Topic; D004054:Diethylstilbestrol / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D004338:Drug Combinations; D045166:Estradiol Congeners / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D004997:Ethinyl Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008535:Megestrol / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000097:blood / Q000627:therapeutic use; D019290:Megestrol Acetate; D008875:Middle Aged; D009919:Orchiectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D004338:Drug Combinations; D045166:Estradiol Congeners; D004997:Ethinyl Estradiol; D004054:Diethylstilbestrol; D008535:Megestrol; D019290:Megestrol Acetate